Search

Your search keyword '"Brentjens, Renier J"' showing total 695 results
Start Over Author "Brentjens, Renier J"
695 results on '"Brentjens, Renier J"'

2. Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors

Author

Zakrzewski, Johannes L., Suh, David, Markley, John C., Smith, Odette M., King, Christopher, Goldberg, Gabrielle L., Jenq, Robert, Holland, Amanda M., Grubin, Jeremy, Cabrera-Perez, Javier, Brentjens, Renier J., Lu, Sydney X., Rizzuto, Gabrielle, Sant’Angelo, Derek B., Riviere, Isabelle, Sadelain, Michel, Heller, Glenn, Zúñiga-Pflücker, Juan Carlos, Lu, Chen, and van den Brink, Marcel R. M.

Published
2024
Full Text
View/download PDF

3. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results

Author

Park, Jae H., Nath, Karthik, Devlin, Sean M., Sauter, Craig S., Palomba, M. Lia, Shah, Gunjan, Dahi, Parastoo, Lin, Richard J., Scordo, Michael, Perales, Miguel-Angel, Shouval, Roni, Tomas, Ana Alarcon, Cathcart, Elizabeth, Mead, Elena, Santomasso, Bianca, Holodny, Andrei, Brentjens, Renier J., Riviere, Isabelle, and Sadelain, Michel

Published
2023
Full Text
View/download PDF

5. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Author

Smith, Melody, Dai, Anqi, Ghilardi, Guido, Amelsberg, Kimberly V., Devlin, Sean M., Pajarillo, Raymone, Slingerland, John B., Beghi, Silvia, Herrera, Pamela S., Giardina, Paul, Clurman, Annelie, Dwomoh, Emmanuel, Armijo, Gabriel, Gomes, Antonio L. C., Littmann, Eric R., Schluter, Jonas, Fontana, Emily, Taur, Ying, Park, Jae H., Palomba, Maria Lia, Halton, Elizabeth, Ruiz, Josel, Jain, Tania, Pennisi, Martina, Afuye, Aishat Olaide, Perales, Miguel-Angel, Freyer, Craig W., Garfall, Alfred, Gier, Shannon, Nasta, Sunita, Landsburg, Daniel, Gerson, James, Svoboda, Jakub, Cross, Justin, Chong, Elise A., Giralt, Sergio, Gill, Saar I., Riviere, Isabelle, Porter, David L., Schuster, Stephen J., Sadelain, Michel, Frey, Noelle, Brentjens, Renier J., June, Carl H., Pamer, Eric G., Peled, Jonathan U., Facciabene, Andrea, van den Brink, Marcel R. M., and Ruella, Marco

Published
2023
Full Text
View/download PDF

6. Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant

Author

Fabrizio, Vanessa A, Kernan, Nancy A, Boulad, Farid, Cancio, Maria, Allen, Jennifer, Higman, Meghan, Margossian, Steven P, Mauguen, Audrey, Prockop, Susan, Scaradavou, Andromachi, Shah, Niketa, Spitzer, Barbara, Stieglitz, Elliot, Yeager, Nicholas, O’Reilly, Richard J, Brentjens, Renier J, Jan Boelens, Jaap, and Curran, Kevin J

Subjects
Stem Cell Research - Nonembryonic - Human, Pediatric, Stem Cell Research, Clinical Research, Transplantation, Cancer, Clinical Trials and Supportive Activities, Regenerative Medicine, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Child, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Immunotherapy, Adoptive, Infant, Neoplasm Recurrence, Local, Retrospective Studies, T-Lymphocytes, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Immunology
Abstract

To define the tolerability and outcome of allogeneic hematopoietic stem cell transplant (allo-HSCT) following CAR T-cell therapy, we retrospectively reviewed pediatric/young adult patients with relapsed/refractory B-ALL who underwent this treatment. Fifteen patients (median age 13 years; range 1-20 years) with a median potential follow-up of 39 months demonstrated 24-month cumulative incidence of relapse, cumulative incidence of TRM, and OS of 16% (95% CI: 0-37%), 20% (95% CI: 0-40%), and 80% (95% CI: 60-100%), respectively. Severe toxicity following CAR T cells did not impact OS (p = 0.27), while greater time from CAR T cells to allo-HSCT (>80 days) was associated with a decrease in OS. In comparing CD34-selected T-cell depleted (TCD; n = 9) vs unmodified (n = 6) allo-HSCT, the cumulative incidence of relapse, TRM, and OS at 24 months was 22% (95% CI: 0-49%) vs 0% (p = 0.14), 0% vs 50% [95% CI: 10-90%] (p = 0.02) and 100% vs 50% [95% CI: 10-90%] (p = 0.02). In this small cohort of patients, CAR T cells followed by a CD34-selected TCD allo-HSCT appears to result in less TRM and favorable OS when compared with unmodified allo-HSCT. There was no evidence that disease control was impacted by the type of consolidative allo-HSCT, which demonstrates the feasibility of this approach.

Published
2020

7. CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function

Author

Kuhn, Nicholas F, Lopez, Andrea V, Li, Xinghuo, Cai, Winson, Daniyan, Anthony F, and Brentjens, Renier J

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Immunization, Vaccine Related, Biotechnology, 1.1 Normal biological development and functioning, Underpinning research, Inflammatory and immune system, Adaptive Immunity, Animals, Antigen Presentation, Antigens, CD, Basic-Leucine Zipper Transcription Factors, CD11b Antigen, CD40 Ligand, CD8-Positive T-Lymphocytes, Dendritic Cells, Female, Gene Expression, Immunity, Innate, Immunophenotyping, Immunotherapy, Adoptive, Integrin alpha Chains, Lymphoma, B-Cell, Mice, Mice, Inbred BALB C, Mice, Knockout, Neoplasm Transplantation, Receptors, Chimeric Antigen, Repressor Proteins
Abstract

While effective in specific settings, adoptive chimeric antigen receptor (CAR) T cell therapy for cancer requires further improvement and optimization. Our previous results show that CD40L-overexpressing CAR T cells mobilize endogenous immune effectors, resulting in improved antitumor immunity. However, the cell populations required for this protective effect remain to be identified. Here we show, by analyzing Batf3-/- mice lacking the CD103+ conventional dendritic cell type 1 (cDC1) subpopulation important for antigen cross-presentation, that CD40L-overexpressing CAR T cells elicit an impaired antitumor response in the absence of cDC1s. We further find that CD40L-overexpressing CAR T cells stimulate tumor-resident CD11b-CD103- double-negative (DN) cDCs to proliferate and differentiate into cDC1s in wild-type mice. Finally, re-challenge experiments show that endogenous CD8+ T cells are required for protective antitumor memory in this setting. Our findings thus demonstrate the stimulatory effect of CD40L-overexpressing CAR T cells on innate and adaptive immune cells, and provide a rationale for using CD40L-overexpressing CAR T cells to improve immunotherapy responses.

Published
2020

8. Developing a membrane-proximal CD33-targeting CAR T cell

Author

Freeman, Ruby, primary, Shahid, Sanam, additional, Khan, Abdul G, additional, Mathew, Serena C, additional, Souness, Sydney, additional, Burns, Erin R, additional, Um, Jasmine S, additional, Tanaka, Kento, additional, Cai, Winson, additional, Yoo, Sarah, additional, Dunbar, Andrew, additional, Park, Young, additional, McAvoy, Devin, additional, Hosszu, Kinga K, additional, Levine, Ross L, additional, Boelens, Jaap Jan, additional, Lorenz, Ivo C, additional, Brentjens, Renier J, additional, and Daniyan, Anthony F, additional

Published
2024
Full Text
View/download PDF

10. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Author

Smith, Melody, Dai, Anqi, Ghilardi, Guido, Amelsberg, Kimberly V., Devlin, Sean M., Pajarillo, Raymone, Slingerland, John B., Beghi, Silvia, Herrera, Pamela S., Giardina, Paul, Clurman, Annelie, Dwomoh, Emmanuel, Armijo, Gabriel, Gomes, Antonio L. C., Littmann, Eric R., Schluter, Jonas, Fontana, Emily, Taur, Ying, Park, Jae H., Palomba, Maria Lia, Halton, Elizabeth, Ruiz, Josel, Jain, Tania, Pennisi, Martina, Afuye, Aishat Olaide, Perales, Miguel-Angel, Freyer, Craig W., Garfall, Alfred, Gier, Shannon, Nasta, Sunita, Landsburg, Daniel, Gerson, James, Svoboda, Jakub, Cross, Justin, Chong, Elise A., Giralt, Sergio, Gill, Saar I., Riviere, Isabelle, Porter, David L., Schuster, Stephen J., Sadelain, Michel, Frey, Noelle, Brentjens, Renier J., June, Carl H., Pamer, Eric G., Peled, Jonathan U., Facciabene, Andrea, van den Brink, Marcel R. M., and Ruella, Marco

Published
2022
Full Text
View/download PDF

12. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models

Author

Jaspers, Janneke E., Khan, Jonathan F., Godfrey, William D., Lopez, Andrea V., Ciampricotti, Metamia, Rudin, Charles M., and Brentjens, Renier J.

Subjects
Gene expression -- Health aspects, Lung cancer, Small cell -- Genetic aspects -- Development and progression -- Care and treatment, Interleukin-18 -- Health aspects, Health care industry
Abstract

Patients with small cell lung cancer (SCLC) generally have a poor prognosis and a median overall survival of only about 13 months, indicating the urgent need for novel therapies. Delta-like protein 3 (DLL3) has been identified as a tumor- specific cell surface marker on neuroendocrine cancers, including SCLC. In this study, we developed a chimeric antigen receptor (CAR) against DLL3 that displays antitumor efficacy in xenograft and murine SCLC models. CAR T cell expression of the proinflammatory cytokine IL-18 greatly enhanced the potency of DLL3- targeting CAR T cell therapy. In a murine metastatic SCLC model, IL-18 production increased the activation of both CAR T cells and endogenous tumor-infiltrating lymphocytes. We also observed an increased infiltration, repolarization, and activation of antigen-presenting cells. Additionally, human IL-18-secreting anti-DLL3 CAR T cells showed an increased memory phenotype, less exhaustion, and induced durable responses in multiple SCLC models, an effect that could be further enhanced with anti-PD-1 blockade. All together, these results define DLL3-targeting CAR T cells that produce IL-18 as a potentially promising novel strategy against DLL3-expressing solid tumors., Introduction Small cell lung cancer (SCLC) accounts for about 15% of lung cancers, and two-thirds of cases are metastatic at the time of diagnosis (1). Despite initial sensitivity to chemotherapy, [...]

Published
2023
Full Text
View/download PDF

14. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System

Author

Avanzi, Mauro P, Yeku, Oladapo, Li, Xinghuo, Wijewarnasuriya, Dinali P, van Leeuwen, Dayenne G, Cheung, Kenneth, Park, Hyebin, Purdon, Terence J, Daniyan, Anthony F, Spitzer, Matthew H, and Brentjens, Renier J

Subjects
Biological Sciences, Lymphoma, Pediatric Cancer, Vaccine Related, Pediatric, Rare Diseases, Immunization, Gene Therapy, Cancer, Hematology, Genetics, Biotechnology, 5.2 Cellular and gene therapies, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Animals, Antineoplastic Agents, Autocrine Communication, B-Lymphocytes, Cell Proliferation, Cell Survival, Disease Models, Animal, Humans, Immune System, Immunotherapy, Immunotherapy, Adoptive, Interleukin-18, Mice, Inbred C57BL, Mice, SCID, Neoplasms, Signal Transduction, T-Lymphocytes, Tumor Microenvironment, Xenograft Model Antitumor Assays, B-ALL, CAR T cell, IL-18, MUC16, adoptive transfer, armored CAR, chimeric antigen receptor, interleukin-18, ovarian cancer, Biochemistry and Cell Biology, Medical Physiology, Biological sciences
Abstract

Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of adoptively transferred CAR T cells, antigen-negative relapses, and impairment by an immunosuppressive tumor microenvironment. Improvements in CAR T cell design are required to enhance clinical efficacy, as well as broaden the applicability of this technology. Here, we demonstrate that interleukin-18 (IL-18)-secreting CAR T cells exhibit enhanced in vivo expansion and persistence and significantly increase long-term survival in syngeneic mouse models of both hematological and solid malignancies. In addition, we demonstrate that IL-18-secreting CAR T cells are capable of modulating the tumor microenvironment, as well as enhancing an effective endogenous anti-tumor immune response. IL-18-secreting CAR T cells represent a promising strategy to enhance the clinical outcomes of adoptive T cell therapy.

Published
2018

15. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

Author

Pennisi, Martina, Sanchez-Escamilla, Miriam, Flynn, Jessica R., Shouval, Roni, Alarcon Tomas, Ana, Silverberg, Mari Lynn, Batlevi, Connie, Brentjens, Renier J., Dahi, Parastoo B., Devlin, Sean M., Diamonte, Claudia, Giralt, Sergio, Halton, Elizabeth F., Jain, Tania, Maloy, Molly, Mead, Elena, Palomba, Maria Lia, Ruiz, Josel, Santomasso, Bianca, Sauter, Craig S., Scordo, Michael, Shah, Gunjan L., Park, Jae H., Yanez San Segundo, Lucrecia, and Perales, Miguel-Angel

Published
2021
Full Text
View/download PDF

19. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

Author

Curran, Kevin J., Margossian, Steven P., Kernan, Nancy A., Silverman, Lewis B., Williams, David A., Shukla, Neerav, Kobos, Rachel, Forlenza, Christopher J., Steinherz, Peter, Prockop, Susan, Boulad, Farid, Spitzer, Barbara, Cancio, Maria I., Boelens, Jaap Jan, Kung, Andrew L., Khakoo, Yasmin, Szenes, Victoria, Park, Jae H., Sauter, Craig S., Heller, Glenn, Wang, Xiuyan, Senechal, Brigitte, O'Reilly, Richard J., Riviere, Isabelle, Sadelain, Michel, and Brentjens, Renier J.

Published
2019
Full Text
View/download PDF

21. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma

Author

Sauter, Craig S., Senechal, Brigitte, Rivière, Isabelle, Ni, Ai, Bernal, Yvette, Wang, Xiuyan, Purdon, Terence, Hall, Malloury, Singh, Ashvin N., Szenes, Victoria Z., Yoo, Sarah, Dogan, Ahmet, Wang, Yongzeng, Moskowitz, Craig H., Giralt, Sergio, Matasar, Matthew J., Perales, Miguel-Angel, Curran, Kevin J., Park, Jae, Sadelain, Michel, and Brentjens, Renier J.

Published
2019
Full Text
View/download PDF

31. Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

Author

Smith, Eric L., primary, Mailankody, Sham, primary, Staehr, Mette, primary, Wang, Xiuyan, primary, Senechal, Brigitte, primary, Purdon, Terence J., primary, Daniyan, Anthony F., primary, Geyer, Mark B., primary, Goldberg, Aaron D., primary, Mead, Elena, primary, Santomasso, Bianca D., primary, Landa, Jonathan, primary, Rimner, Andreas, primary, Riviere, Isabelle, primary, Landgren, Ola, primary, and Brentjens, Renier J., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

Author

Smith, Eric L., primary, Mailankody, Sham, primary, Staehr, Mette, primary, Wang, Xiuyan, primary, Senechal, Brigitte, primary, Purdon, Terence J., primary, Daniyan, Anthony F., primary, Geyer, Mark B., primary, Goldberg, Aaron D., primary, Mead, Elena, primary, Santomasso, Bianca D., primary, Landa, Jonathan, primary, Rimner, Andreas, primary, Riviere, Isabelle, primary, Landgren, Ola, primary, and Brentjens, Renier J., primary

Published
2023
Full Text
View/download PDF

34. Data from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Author

Adusumilli, Prasad S., primary, Zauderer, Marjorie G., primary, Rivière, Isabelle, primary, Solomon, Stephen B., primary, Rusch, Valerie W., primary, O'Cearbhaill, Roisin E., primary, Zhu, Amy, primary, Cheema, Waseem, primary, Chintala, Navin K., primary, Halton, Elizabeth, primary, Pineda, John, primary, Perez-Johnston, Rocio, primary, Tan, Kay See, primary, Daly, Bobby, primary, Araujo Filho, Jose A., primary, Ngai, Daniel, primary, McGee, Erin, primary, Vincent, Alain, primary, Diamonte, Claudia, primary, Sauter, Jennifer L., primary, Modi, Shanu, primary, Sikder, Devanjan, primary, Senechal, Brigitte, primary, Wang, Xiuyan, primary, Travis, William D., primary, Gönen, Mithat, primary, Rudin, Charles M., primary, Brentjens, Renier J., primary, Jones, David R., primary, and Sadelain, Michel, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figures from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Author

Adusumilli, Prasad S., primary, Zauderer, Marjorie G., primary, Rivière, Isabelle, primary, Solomon, Stephen B., primary, Rusch, Valerie W., primary, O'Cearbhaill, Roisin E., primary, Zhu, Amy, primary, Cheema, Waseem, primary, Chintala, Navin K., primary, Halton, Elizabeth, primary, Pineda, John, primary, Perez-Johnston, Rocio, primary, Tan, Kay See, primary, Daly, Bobby, primary, Araujo Filho, Jose A., primary, Ngai, Daniel, primary, McGee, Erin, primary, Vincent, Alain, primary, Diamonte, Claudia, primary, Sauter, Jennifer L., primary, Modi, Shanu, primary, Sikder, Devanjan, primary, Senechal, Brigitte, primary, Wang, Xiuyan, primary, Travis, William D., primary, Gönen, Mithat, primary, Rudin, Charles M., primary, Brentjens, Renier J., primary, Jones, David R., primary, and Sadelain, Michel, primary

Published
2023
Full Text
View/download PDF

36. Data from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

Author

Santomasso, Bianca D., primary, Park, Jae H., primary, Salloum, Darin, primary, Riviere, Isabelle, primary, Flynn, Jessica, primary, Mead, Elena, primary, Halton, Elizabeth, primary, Wang, Xiuyan, primary, Senechal, Brigitte, primary, Purdon, Terence, primary, Cross, Justin R., primary, Liu, Hui, primary, Vachha, Behroze, primary, Chen, Xi, primary, DeAngelis, Lisa M., primary, Li, Daniel, primary, Bernal, Yvette, primary, Gonen, Mithat, primary, Wendel, Hans-Guido, primary, Sadelain, Michel, primary, and Brentjens, Renier J., primary

Published
2023
Full Text
View/download PDF

37. Figure S1, Figure S2, Figure S3, Figure S4 from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

Author

Santomasso, Bianca D., primary, Park, Jae H., primary, Salloum, Darin, primary, Riviere, Isabelle, primary, Flynn, Jessica, primary, Mead, Elena, primary, Halton, Elizabeth, primary, Wang, Xiuyan, primary, Senechal, Brigitte, primary, Purdon, Terence, primary, Cross, Justin R., primary, Liu, Hui, primary, Vachha, Behroze, primary, Chen, Xi, primary, DeAngelis, Lisa M., primary, Li, Daniel, primary, Bernal, Yvette, primary, Gonen, Mithat, primary, Wendel, Hans-Guido, primary, Sadelain, Michel, primary, and Brentjens, Renier J., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Material from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Author

Adusumilli, Prasad S., primary, Zauderer, Marjorie G., primary, Rivière, Isabelle, primary, Solomon, Stephen B., primary, Rusch, Valerie W., primary, O'Cearbhaill, Roisin E., primary, Zhu, Amy, primary, Cheema, Waseem, primary, Chintala, Navin K., primary, Halton, Elizabeth, primary, Pineda, John, primary, Perez-Johnston, Rocio, primary, Tan, Kay See, primary, Daly, Bobby, primary, Araujo Filho, Jose A., primary, Ngai, Daniel, primary, McGee, Erin, primary, Vincent, Alain, primary, Diamonte, Claudia, primary, Sauter, Jennifer L., primary, Modi, Shanu, primary, Sikder, Devanjan, primary, Senechal, Brigitte, primary, Wang, Xiuyan, primary, Travis, William D., primary, Gönen, Mithat, primary, Rudin, Charles M., primary, Brentjens, Renier J., primary, Jones, David R., primary, and Sadelain, Michel, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Tables from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Author

Adusumilli, Prasad S., primary, Zauderer, Marjorie G., primary, Rivière, Isabelle, primary, Solomon, Stephen B., primary, Rusch, Valerie W., primary, O'Cearbhaill, Roisin E., primary, Zhu, Amy, primary, Cheema, Waseem, primary, Chintala, Navin K., primary, Halton, Elizabeth, primary, Pineda, John, primary, Perez-Johnston, Rocio, primary, Tan, Kay See, primary, Daly, Bobby, primary, Araujo Filho, Jose A., primary, Ngai, Daniel, primary, McGee, Erin, primary, Vincent, Alain, primary, Diamonte, Claudia, primary, Sauter, Jennifer L., primary, Modi, Shanu, primary, Sikder, Devanjan, primary, Senechal, Brigitte, primary, Wang, Xiuyan, primary, Travis, William D., primary, Gönen, Mithat, primary, Rudin, Charles M., primary, Brentjens, Renier J., primary, Jones, David R., primary, and Sadelain, Michel, primary

Published
2023
Full Text
View/download PDF

40. Table S1, Table S2, Table S3, Table S4 from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

Author

Santomasso, Bianca D., primary, Park, Jae H., primary, Salloum, Darin, primary, Riviere, Isabelle, primary, Flynn, Jessica, primary, Mead, Elena, primary, Halton, Elizabeth, primary, Wang, Xiuyan, primary, Senechal, Brigitte, primary, Purdon, Terence, primary, Cross, Justin R., primary, Liu, Hui, primary, Vachha, Behroze, primary, Chen, Xi, primary, DeAngelis, Lisa M., primary, Li, Daniel, primary, Bernal, Yvette, primary, Gonen, Mithat, primary, Wendel, Hans-Guido, primary, Sadelain, Michel, primary, and Brentjens, Renier J., primary

Published
2023
Full Text
View/download PDF

48. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy

Author

Smith, Melody, primary, Dai, Anqi, additional, Ghilardi, Guido, additional, Amelsberg, Kimberly V., additional, Devlin, Sean M., additional, Pajarillo, Raymone, additional, Slingerland, John B., additional, Beghi, Silvia, additional, Herrera, Pamela S., additional, Giardina, Paul, additional, Clurman, Annelie, additional, Dwomoh, Emmanuel, additional, Armijo, Gabriel, additional, Gomes, Antonio L. C., additional, Littmann, Eric R., additional, Schluter, Jonas, additional, Fontana, Emily, additional, Taur, Ying, additional, Park, Jae H., additional, Palomba, Maria Lia, additional, Halton, Elizabeth, additional, Ruiz, Josel, additional, Jain, Tania, additional, Pennisi, Martina, additional, Afuye, Aishat Olaide, additional, Perales, Miguel-Angel, additional, Freyer, Craig W., additional, Garfall, Alfred, additional, Gier, Shannon, additional, Nasta, Sunita, additional, Landsburg, Daniel, additional, Gerson, James, additional, Svoboda, Jakub, additional, Cross, Justin, additional, Chong, Elise A., additional, Giralt, Sergio, additional, Gill, Saar I., additional, Riviere, Isabelle, additional, Porter, David L., additional, Schuster, Stephen J., additional, Sadelain, Michel, additional, Frey, Noelle, additional, Brentjens, Renier J., additional, June, Carl H., additional, Pamer, Eric G., additional, Peled, Jonathan U., additional, Facciabene, Andrea, additional, van den Brink, Marcel R. M., additional, and Ruella, Marco, additional

Published
2022
Full Text
View/download PDF

50. GPRC5D-Targeted CAR T Cells for Myeloma

Author

Mailankody, Sham, primary, Devlin, Sean M., additional, Landa, Jonathan, additional, Nath, Karthik, additional, Diamonte, Claudia, additional, Carstens, Elizabeth J., additional, Russo, Douglas, additional, Auclair, Romany, additional, Fitzgerald, Lisa, additional, Cadzin, Briana, additional, Wang, Xiuyan, additional, Sikder, Devanjan, additional, Senechal, Brigitte, additional, Bermudez, Vladimir P., additional, Purdon, Terence J., additional, Hosszu, Kinga, additional, McAvoy, Devin P., additional, Farzana, Tasmin, additional, Mead, Elena, additional, Wilcox, Jessica A., additional, Santomasso, Bianca D., additional, Shah, Gunjan L., additional, Shah, Urvi A., additional, Korde, Neha, additional, Lesokhin, Alexander, additional, Tan, Carlyn R., additional, Hultcrantz, Malin, additional, Hassoun, Hani, additional, Roshal, Mikhail, additional, Sen, Filiz, additional, Dogan, Ahmet, additional, Landgren, Ola, additional, Giralt, Sergio A., additional, Park, Jae H., additional, Usmani, Saad Z., additional, Rivière, Isabelle, additional, Brentjens, Renier J., additional, and Smith, Eric L., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results